The U.S. Food and Drug Administration recently approved a monthly treatment for adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis, according to a report in HealthNewsDigest.com. All three of these conditions are characterized by pain, limited movement and pain which occur when the body’s immune system attacks joints.
The drug Simponi, which is administered via an injection under the skin, is intended for use in combination with the immunosuppressant drug methotrexate for those suffering from rheumatoid arthritis. It may also be used with or without methotrexate for psoriatic arthritis and on its own to treat patients with ankylosing spondylitis, a chronic inflammatory arthritis of the spine. In clinical trials, patients who received Simponi for one of the three conditions showed improvements in the signs and symptoms common to their form of arthritis.
To read the full story, click FDA Approves Simponi for Arthritis Treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment